Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Holdings Lifted by Signaturefd LLC

Signaturefd LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 2,511 shares of the company’s stock after buying an additional 125 shares during the quarter. Signaturefd LLC’s holdings in Neurocrine Biosciences were worth $331,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Headinvest LLC purchased a new position in Neurocrine Biosciences in the third quarter valued at about $28,000. Lindbrook Capital LLC boosted its stake in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after acquiring an additional 96 shares in the last quarter. BluePath Capital Management LLC bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $35,000. Sunbelt Securities Inc. boosted its stake in shares of Neurocrine Biosciences by 34.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock worth $37,000 after acquiring an additional 83 shares in the last quarter. Finally, Fifth Third Bancorp boosted its stake in shares of Neurocrine Biosciences by 51.3% during the 3rd quarter. Fifth Third Bancorp now owns 622 shares of the company’s stock worth $70,000 after acquiring an additional 211 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on NBIX shares. Wedbush reiterated an “outperform” rating and set a $147.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, April 17th. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. HC Wainwright reiterated a “buy” rating and set a $150.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Finally, The Goldman Sachs Group boosted their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $142.38.

Insider Activity

In other news, insider Eric Benevich sold 75,000 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00. Following the sale, the insider now directly owns 40,778 shares in the company, valued at approximately $5,683,637.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Ingrid Delaet sold 200 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $140.00, for a total value of $28,000.00. Following the sale, the insider now directly owns 7,507 shares in the company, valued at approximately $1,050,980. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Eric Benevich sold 75,000 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00. Following the sale, the insider now owns 40,778 shares in the company, valued at $5,683,637.64. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 186,994 shares of company stock worth $25,806,409. Company insiders own 4.40% of the company’s stock.

Neurocrine Biosciences Stock Down 0.9 %

Neurocrine Biosciences stock opened at $137.76 on Friday. The business has a 50 day moving average price of $136.56 and a two-hundred day moving average price of $127.69. The stock has a market cap of $13.71 billion, a price-to-earnings ratio of 56.93 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 12 month low of $89.04 and a 12 month high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The firm had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. During the same quarter in the prior year, the firm posted $0.88 EPS. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.